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 Note from the Chief Technical Editor 
As Chief Technical Editor, I am delighted and honored to present the 
third issue of The University of the Pacific Law Review, Volume 51. 
As The University of the Pacific Law Review’s Chief Technical 
Editor, my role is to examine the footnotes of each article to ensure 
compliance with the Harvard Bluebook and the McGeorge Style Manual. 
Each article undergoes multiple rounds of review—first by the staff writers, 
then by the primary editors, and finally by the Board of Editors. The 
University of the Pacific Law Review strives to output quality, thought-
provoking articles and the accuracy of footnotes is an important part of this 
aim. 
Today, the United States is the world’s largest pharmaceutical market. 
This issue of Volume 51 explores important legal issues surrounding the 
rapidly growing pharmaceutical industry and its regulation. In his article, 
Professor Holman voices concerns about the way pharmaceutical companies 
use the patent system in the United States and offers suggestions to target the 
misuse of patents without impairing the patenting of pharmaceutical 
innovations. Professor Rose and Ms. Rice’s article explores the Food and 
Drug Administration’s recent Biosimilar Action Plan and analyzes its 
effectiveness in balancing innovation and competition in the United States. 
The remaining articles in this issue also contain meaningful discussions of the 
legal issues surrounding the pharmaceutical industry. 
The University of the Pacific Law Review, Volume 51 would not be 
possible without the collaboration and efforts of the outstanding Board of 
Editors, with whom it has been a true pleasure to work. I owe my sincere 
thanks to DJ Mico, my proofreading counterpart, who is tasked with 
reviewing the content of each article to eliminate any grammatical or 
typographical errors. Also, I would like to specially thank Hayley Graves, our 
Editor-in-Chief, for her unmatched dedication to this publication. We 
genuinely hope that you enjoy this issue. 
Amy Seilliere 
Chief Technical Editor 
The University of the Pacific Law Review, 
Volume 51 
